Treatment of Diabetic Macular Edema With 0.5mg Intraocular Ranibizumab (Lucentis)

Inclusion Criteria: 1. diabetic macular edema with center involvement in at least one eye 2. patients with a central retinal thickness 3. patients with a BCVA of 78-24 EDTRS letters 4. decrease in vision is due to DME and not due to other causes, in the opinion of the investigator 5. Type 1 or type 2 diabetes mellitus diagnosed 2 years prior to screening Exclusion Criteria: 1. history or evidence of severe cardiac disease 2. clinical or medical history uncontrolled hypertension or diabetes 3. of unstable angina, acute coronary syndrome, myocardial infarction or revascularization with 6 months 4. ventricular tachyarrhythmias requiring ongoing treatment 5. history or evidence clinically significant peripheral vascular disease, such a intermittent claudication or prior amputation 6. clinically significant impaired renal or hepatic function